Zacks Investment Research upgraded shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a hold rating to a buy rating in a research report released on Tuesday, August 8th. The brokerage currently has $1.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
OCRX has been the topic of several other reports. Aegis restated a buy rating and issued a $3.00 price objective on shares of Ocera Therapeutics in a research report on Monday, April 17th. HC Wainwright reaffirmed a buy rating and issued a $4.00 target price on shares of Ocera Therapeutics in a report on Wednesday, May 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $3.85.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative return on equity of 175.02% and a negative net margin of 4,416.26%. On average, analysts anticipate that Ocera Therapeutics will post ($1.20) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Ocera Therapeutics, Inc. (OCRX) Lifted to Buy at Zacks Investment Research” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/zacks-investment-research-upgrades-ocera-therapeutics-inc-ocrx-to-buy-updated.html.
A number of large investors have recently modified their holdings of OCRX. Perceptive Advisors LLC bought a new stake in shares of Ocera Therapeutics during the first quarter valued at $2,817,000. Hikari Power Ltd acquired a new position in Ocera Therapeutics during the first quarter worth approximately $328,000. Virtu KCG Holdings LLC boosted its position in Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 141,040 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares in the last quarter. 20.86% of the stock is currently owned by institutional investors.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Ocera Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocera Therapeutics Inc. and related companies.